Search Results - "Hanatani, Tadaaki"

CiRA iPSC seed stocks (CiRA's iPSC Stock Project) by Hanatani, Tadaaki, Takasu, Naoko

“…In Japan, induced pluripotent stem cell (iPSC) Stock Project has started from 2013. The goal of the Project is to manufacture and release clinical-grade HLA…”
Get full text

Quality control guidelines for clinical-grade human induced pluripotent stem cell lines by Sullivan, Stephen, Stacey, Glyn N, Akazawa, Chihiro, Aoyama, Naoki, Baptista, Ricardo, Bedford, Patrick, Bennaceur Griscelli, Annelise, Chandra, Amit, Elwood, Ngaire, Girard, Mathilde, Kawamata, Shin, Hanatani, Tadaaki, Latsis, Theodoros, Lin, Stephen, Ludwig, Tenneille E, Malygina, Tamara, Mack, Amanda, Mountford, Joanne C, Noggle, Scott, Pereira, Lygia V, Price, Jack, Sheldon, Michael, Srivastava, Alok, Stachelscheid, Harald, Velayudhan, Shaji R, Ward, Natalie J, Turner, Marc L, Barry, Jacqueline, Song, Jihwan

“…Use of clinical-grade human induced pluripotent stem cell (iPSC) lines as a starting material for the generation of cellular therapeutics requires…”
Get full text

Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials by Sai, Kimie, Yoshida, Akiomi, Hanatani, Tadaaki, Imatoh, Takuya, Takeuchi, Masahiro, Narukawa, Mamoru, Watanabe, Hiroshi, Uyama, Yoshiaki, Saito, Yoshiro

“…Aims This study aimed to identify population/regional differences in drug efficacy and the influencing factors among East Asians to be considered when planning…”
Get full text

Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients by Hanatani, Tadaaki, Sai, Kimie, Tohkin, Masahiro, Segawa, Katsunori, Saito, Yoshiro

“…Background The March 2012 regulatory action issued by the Japanese government signalled the rare but serious complication of lactic acidosis that can occur…”
Get full text

Report of the international conference on manufacturing and testing of pluripotent stem cells by Abbot, Stewart, Agbanyo, Francisca, Ahlfors, Jan-Eric, Baghbaderani, Behnam A., Bartido, Shirley, Bharti, Kapil, Burke, Carl, Carlsson, Bjorn, Cavagnaro, Joy, Creasey, Abla, DiGiusto, David, Francissen, Kathy, Gaffney, Andrew, Goldring, Christopher, Gorba, Thorsten, Griffiths, Elwyn, Hanatani, Tadaaki, Hayakawa, Takao, Heki, Tatsuo, Hoogendoorn, Karin, Kawamata, Shin, Kimura, Hironobu, Kirkeby, Agnete, Knezevic, Ivana, Lebkowski, Jane, Lin, Stephen, Lin-Gibson, Shen, Lubiniecki, Anthony, O'Shea, Orla, Pera, Martin, Petricciani, John, Pigeau, Gary, Ratcliffe, Anthony, Sato, Yoji, Schumann, Gerald G., Shingleton, William, Stacey (Chair), Glyn, Sullivan, Stephen, Svendsen, Clive N., Trouvin, Jean-Hugues, Vandeputte, Joris, Yuan, Bao-Zhu, Zoon, Kathryn

“…Sessions included an overview of past cell therapy (CT) conferences sponsored by the International Alliance for Biological Standardization (IABS). The sessions…”
Get full text

Trends in drug-induced liver injury based on reports of adverse reactions to PMDA in Japan by Sudo, Chie, Maekawa, Keiko, Segawa, Katsunori, Hanatani, Tadaaki, Sai, Kimie, Saito, Yoshiro

“…Reports on drug-related adverse reactions from manufacturing/distributing pharmaceutical companies or medical institutions/pharmacies are regulated under the…”
Get more information

A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale by Hanatani, Tadaaki, Sai, Kimie, Tohkin, Masahiro, Segawa, Katsunori, Kimura, Michio, Hori, Katsuhito, Kawakami, Junichi, Saito, Yoshiro

“…ABSTRACT Purpose Drug‐induced liver injury (DILI) is one of the primary targets for pharmacovigilance using medical information databases (MIDs). Because of…”
Get full text

No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3 by HANATANI, Tadaaki, FUKUDA, Tsuyoshi, ONISHI, Sachi, FUNAE, Yoshihiko, AZUMA, Junichi

“…CYP2C9 is a polymorphic enzyme, and CYP2C9*3 is associated with decreased metabolic activity. In addition to the impaired metabolism, we investigated whether…”
Get full text